Adjuvant chemoradiotherapy in patients (pts) with resectable gastric (GC) or gastroesophageal junction cancer (GEJC): A monoinstitutional experience

被引：0
|
作者：
Soini, Barbara
Pani, Giuseppe
Caffo, Orazio
Frisinghelli, Michela
Veccia, Antonello
Brugnara, Sonia
Caldara, Alessia
DiPasquale, MariaChiara
Ferro, Antonella
Mussari, Salvatore
Murgia, Viviana
Russo, Lucianna
Valduga, Francesco
Tumulo, Salvatore
Galligioni, Enzo
机构：
[1] Med Oncol Santa Chiara Hosp, Trento, Italy
[2] Radiotherapy Santa Chiara Hosp, Trento, Italy
[3] Santa Maria degli Angeli Hosp, Pordenone, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14711
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Adjuvant chemoradiotherapy with carboplatin and a fluoropyrimidine for resectable gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience
    de Bruin, M. A.
    Kunz, P. L.
    Sharma, V. B.
    Norton, J. A.
    Bastidas, J.
    Chang, D. T.
    Koong, A. C.
    Koong, A. C.
    Balise, R. R.
    Ford, J. M.
    Fisher, G. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
    Bai, Y.
    Xu, N.
    Yuan, X.
    Wang, B.
    Li, E.
    Li, X.
    Li, Y.
    Wang, X.
    Yang, S.
    Xu, J.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [3] THE GLOBAL BURDEN OF GASTRIC (GC) AND GASTROESOPHAGEAL JUNCTION (GEJC) CANCERS
    Morlock, R.
    Duran, A.
    Holmstrom, S.
    Casamayor, M.
    Gani, R.
    Pandya, B. J.
    van Engen, A.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A460 - A460
  • [4] Routine care of patients with resectable gastric (GC) and gastroesophageal junction (GEJC) adenocarcinoma - Data of the retrospective perioperative cohort PRIME of the registry platform SAPHIR
    Lordick, F.
    Dechow, T.
    von der Heyde, E.
    Sadjadian, P.
    Schulte, C.
    de Buhr, R.
    Lennartz, C.
    Binninger, A.
    Janicke, M.
    Kruger, S.
    Abromeit, M.
    Lorenzen, S.
    Reinacher-Schick, A.
    Potthoff, k
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 118 - 118
  • [5] What is the outcome of receiving subsequent therapy among patients (pts) with advanced/metastatic (Adv/Met) gastric or gastroesophageal junction cancer (GC/GEJC)? Experience from electronic health records (EHR).
    Le, Dung T.
    Janjigian, Yelena Yuriy
    Ott, Patrick Alexander
    Korytowsky, Beata
    Le, Hannah
    Trong Kim Le
    Zhang, Ying
    Maglinte, Gregory
    Patel, Dhiren
    Shangguan, Tong
    Chau, Ian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Phase Ib trial of cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with advanced hepatocellular carcinoma (HCC), gastric or gastroesophageal junction cancer (GC/GEJC), or colorectal cancer (CRC).
    Spencer, Kristen Renee
    Ramsingh, Giridharan
    Mohamed, Nehal
    Pal, Sumanta K.
    Rimassa, Lorenza
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [7] Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?
    Bai, Rilan
    Chen, Naifei
    Liang, Tingting
    Li, Lingyu
    Lv, Zheng
    Lv, Xiaomin
    Cui, Jiuwei
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
  • [8] Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC)
    Chen, Zhendong
    Bai, Yuxian
    Zhang, Tao
    Ying, Jieer
    Lin, Xiaoyan
    Yang, Liu
    Wang, Jun
    Zhang, Juan
    Yu, Fan
    Fei, Cong
    Huang, Ruiqi
    Li, Jin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [9] Translating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: Prevalence and outcome dataTranslating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: prevalence and outcome data.
    Gardeazabal, Itziar
    Hierro, Cinta
    Viaplana, Cristina
    Nuciforo, Paolo
    Vivancos, Ana
    Mercade, Teresa Macarulla
    Garralda, Elena
    Eugenia Semidey, Maria
    Grau Bejar, Juan Francisco
    Dienstmann, Rodrigo
    Landolfi, Stefania
    Alsina, Maria
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] The potential drug cost impact of nivolumab (N) in patients with advanced/metastatic gastric cancer (GC) or gastroesophageal junction cancer (GEJC) in Canada.
    Virik, Kiran
    Wilson, Robert B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345